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Abstract 
Objective: Anaemia is common among patients with heart failure (HF) and is an 
important prognostic marker.  We sought to determine the prognostic importance of 
anaemia in a large multinational pooled dataset of prospectively enrolled HF 
patients, with the specific aim to determine the prognostic role of anaemia in HF with 
preserved and reduced ejection fraction (HF-PEF and HF-REF respectively).  
Methods: Patients with haemoglobin (Hb) data from the MAGGIC dataset were 
used. Anaemia was defined as Hb <120 g/L in women and <130 g/L in men. HF-PEF 
was defined as EF≥50%; HF-REF was EF<50%. Cox proportional hazard modelling, 
with adjustment for clinically relevant variables, was undertaken to investigate factors 
associated with 3-year all-cause mortality. 
Results: 13,295 patients with HF from 19 studies (9887 with HF-REF and 3408 with 
HF-PEF). The prevalence of anaemia was similar among those with HF-REF and 
HF-PEF (42.8% and 41.6% respectively). Compared to patients with normal Hb 
values, those with anaemia were older, were more likely to have diabetes, ischaemic 
aetiology, NYHA class IV symptoms, lower eGFR, and were more likely to be taking 
diuretic and less likely to be taking a beta-blocker. Patients with anaemia had higher 
all-cause mortality (adjusted hazard ratio [aHR] 1.38, 95% confidence interval 1.25-
1.51), independent of EF group: aHR 1.67 (1.39-1.99) in HF-PEF and aHR 2.49 
(2.13-2.90) in HF-REF.   
Conclusions: Anaemia is an adverse prognostic factor in HF irrespective of EF. The 
prognostic importance of anaemia was greatest in patients with HF-REF.  
 
Key words: anaemia, heart failure, prognosis, ejection fraction 
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Key questions 
 
What is already known about this subject? 
Anaemia is common in heart failure and is associated with adverse prognosis. 
 
What does this study add? 
Anaemia is prognostically important, irrespective of left ventricular ejection fraction. 
Patients with anaemia and heart failure with a reduced ejection fraction have the 
highest mortality; however measurement of haemoglobin can also stratify patients 
with heart failure with preserved ejection fraction into higher and lower risk 
subgroups. 
 
How might this impact on clinical practice? 
As patients with abnormal haemoglobin levels are at increased risk of adverse 
outcome, increased vigilance and optimisation of heart failure management becomes 
all the more important in these HF patients.  
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Introduction 
Anaemia is common and important in heart failure (HF). Anaemia in HF is of 
multifactorial aetiology and is associated with worse symptoms and higher 
mortality.1-6 Several uncertainties remain about the clinical significance of anaemia. 
For example, the Norwegian Heart Failure Registry found that anaemia did not 
predict all-cause mortality in community-dwelling patients with advanced HF.7 A 
recent literature-based meta-analysis has shown that anaemia predicts all-cause 
mortality in patients with HF with both preserved and reduced ejection fraction (HF-
PEF and HF-REF).4 However, this meta-analysis was based on heterogeneous 
inclusion criteria, with inconsistent definitions of anaemia, and as the analysis did not 
include patient-level data, multivariable analyses were not performed. We aimed to 
study the characteristics and prognostic significance of anaemia in patients with HF-
PEF and with HF-REF using pooled patient-level data.  
 
Methods 
The methods for study selection and data extraction for the MAGGIC individual 
patient data meta-analysis have been described previously.8 In brief, we pooled 
individual patient data from 31 studies that prospectively collected all-cause mortality 
among HF patients, and did not restrict entry criteria by EF.  Data from the individual 
studies were re-coded into a uniform format at the Central Co-ordinating Centre at 
the University of Auckland, New Zealand and incorporated into one database. The 
protocol of the meta-analysis was approved by the University of Auckland Human 
Subjects Ethics Committee.   
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This analysis was restricted to those patients for whom haemoglobin (Hb) data at 
baseline were available within the main MAGGIC dataset.8  Anaemia was defined as 
Hb <120 g/L in women and <130 g/L in men.9  Patients were classified into groups 
according to the presence or absence of anaemia and according to ejection fraction 
(HF-PEF or HF-REF).  As in the primary analysis of the MAGGIC dataset, preserved 
EF was defined as EF ≥ 50% (majority assessed by echocardiography).  Reduced 
EF was therefore defined as EF < 50%.    
 
Cox proportional hazard models were used to investigate the association between 
anaemia and 3-year all-cause mortality. Models were adjusted for age, gender, 
ischaemic aetiology, atrial fibrillation (AF), diabetes, hypertension, and eGFR, and 
were stratified by study. An interaction between gender and anaemia was assessed. 
Imputation of missing data was not performed. Cox models were further used to 
model the relationship between Hb level (per 10 g/L) and 3-year mortality per EF 
group.  A statistically significant interaction between Hb and gender within the HF-
PEF group (p=0.01) led to models being stratified by gender. These models were 
adjusted for age only and used a referent concentration of 120-130 g/L for women 
and 130-140 g/L for men. SAS v9.2 was used for all analyses.   
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Results 
Haemoglobin data were available for 13,295 patients from 19 studies. For the whole 
group, mean age was 68 years (SD 12 years), 36% were women, 46% had a history 
of hypertension, 56% ischaemic aetiology of HF, 23% AF, the majority (73%) had 
NYHA Class II or III symptoms of HF, and mean Hb was 126 g/L (SD 25 g/L). 9,887 
patients had HF-REF of whom 4,238 (43%) had anaemia, and 3,408 patients had 
HF-PEF of whom 1,419 (42%) had anaemia. Irrespective of EF group (HF-REF or 
HF-PEF), patients with anaemia were older, more likely to have had a myocardial 
infarction, to have diabetes, ischaemic aetiology of HF, NYHA class IV symptoms, 
lower eGFR, and were more frequently prescribed a diuretic and less likely 
prescribed a beta-blocker, than those without anaemia (p-values < 0.05, Table 1). 
Patients with anaemia were also more likely to have oedema although this 
information was unavailable in 54% of patients. 
Anaemia was associated with higher all-cause mortality among patients with HF-
REF and patients with HF-PEF (Table 1, Figure 1). Among patients with HF-REF, 
1,325 (31.3%) patients with anaemia died compared with 889 (15.7%) patients 
without anaemia; for patients with HF-PEF, 283 (19.9%) patients with anaemia died 
compared with 229 (11.5%) patients without anaemia. In multivariable analysis, the 
presence of anaemia was independently associated with higher risk of death from 
any cause (adjusted hazard ratio [aHR] 1.38, 95% confidence interval 1.25-1.51), as 
were HF-REF, age, male gender, AF, ischaemic aetiology, diabetes, and worsening 
renal function (Table 2).  There was no interaction between anaemia and gender for 
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either EF group (HF-REF p=0.13, HF-PEF p=0.08) therefore these models were not 
stratified by gender. 
The risk of death increased as Hb decreased through the anaemic range for all 
patients.  However the risk of death among women with HF-PEF also increased as 
Hb increased through the non-anaemic range (Figure 2). Only 139 women with HF-
PEF had Hb ≥150 g/L, and although the increase in mortality is close to reaching 
statistical significance (aHR = 1.67, 95% CI 0.99-2.79), this is based on only 23 
deaths in that subgroup. Patient characteristics over the range of Hb values were 
consistent with the trends seen when classified by anaemia status (Supplementary 
Tables 1-4). 
 
Discussion 
The main findings of our study are firstly, HF patients with anaemia were more likely 
to be older, have ischaemic aetiology, and have more severe signs and symptoms.  
Secondly, anaemic patients were less likely to be treated with a beta-blocker and 
more likely to be receiving a diuretic, regardless of whether they had HF-REF or HF-
PEF. Thirdly, anaemia was an independent predictor of adverse outcome for patients 
with HF-REF and those with HF-PEF. 
 
As has been established in a number of prior studies, anaemia is of prognostic 
importance in patients with HF4 10, particularly among those with HF-REF. The 
current analyses clearly now confirm the prognostic importance of anaemia among 
patients with HF-PEF. The worst prognosis was observed among those patients with 
8 
 
anaemia and HF-REF, followed by patients with HF-PEF with anaemia, who had 
similar prognosis to those with HF-REF without anaemia. We have previously 
reported from this meta-analysis that patients with HF-PEF have lower mortality than 
patients with HF-REF.8 These findings suggest that one simple marker, the Hb, is 
able to further stratify patients with HF-PEF (and HF-REF) into higher and lower risk 
subgroups. The influence of anaemia on mortality was independent of other common 
predictors of outcome regardless of the EF group.  
 
Previous studies involving patients with HF with iron deficiency (with or without 
anaemia) have shown that treatment with iron supplements results in an 
improvement in quality of life and functional capacity.5 11  However, the recent 
Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial, which 
assessed the use of this erythropoietin analogue in patients with HF-REF and 
anaemia, showed that correction of anaemia did not improve survival.12 13 Although 
large-scale clinical outcome studies of the effects of erythropoietin analogues in 
patients with HF-PEF and anaemia are not available, a recent phase II study 
reported that treatment with epoetin alfa did not improve left ventricular volumes or 
mass, submaximal exercise capacity or quality of life.14 These results suggest that 
anaemia may be a marker of poor prognosis rather than a therapeutic target for 
patients with HF. Reflecting these results, the recent American College of Physicians 
guidelines on treatment of anaemia in patients with heart disease now recommend 
against the use of erythropoiesis-stimulating agents in patients with anaemia and 
heart failure.15 Small scale studies of the effects of intravenous iron infusions in 
patients with heart failure and anaemia with low ferritin levels suggest beneficial 
effects on exercise tolerance and quality of life.11  However, longer term effects on 
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clinical events remain uncertain. Such treatment is not approved for use in the 
United States at present15, although is discussed as a potential option for appropriate 
patients in the 2012 ESC Heart Failure Guidelines.16  
 
The causes of anaemia in chronic HF may be multifactorial and include 
haemodilution, iron loss or impaired utilisation, chronic renal failure, bone marrow 
suppression, inflammation and chronic disease.2 17 18 Across a range of clinical trials 
and cohort studies, including the RED-HF trial13 and the Study of Anaemia in Heart 
Failure Trial (STAMINA-HeFT)19, community studies20 21, and those in the current 
analysis, heart failure patients with anaemia were older and had worse functional 
capacity than those who were not anaemic.  Advanced HF is a pro-inflammatory 
condition18 which, together with the common comorbidities such as renal 
dysfunction, will contribute to increasing frailty.20 Thus anaemia is a common co-
morbidity which is prognostically important.6 22 23 
 
The current data suggest the possibility of higher mortality among women with non-
anaemic, higher Hb levels. The prognostic significance of higher Hb levels among 
women with HF-PEF may be influenced by other gender-related differences in 
cardiovascular disease, such as proximal arterial stiffness.23 24 Women may be more 
susceptible to the deleterious effects of greater pulsatile and early arterial load on 
diastolic function and ventricular-arterial interaction24, and higher Hb levels (and 
blood viscosity) may enhance vascular stiffness in women more than in men.25  
However women with HF-PEF and Hb > 150 g/L were not older than other women 
with HF-PEF, and did not have a significantly higher prevalence of hypertension, so 
the reasons behind the suggested increase in mortality in this group are unclear. 
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While a “U-shaped” relationship between Hb and mortality in patients with HF has 
been reported in previous studies26 27, this finding needs further evaluation.  
 
Our study has some limitations. The definition of anaemia is based on a single 
determination of the blood count, and other potentially relevant information, such as 
treatment for anaemia, intercurrent bleeding, fluid overload, or other variations in Hb 
levels were not available, or not available with sufficient data. With regards to drug 
therapy, we lack information on contraindications or intolerance to evidence-based 
drugs. Finally, we were unable to adjust the analyses for the extent and nature of 
unmeasured comorbidity other than the clinical variables incorporated in the 
multivariable model. Variables were included on the basis of clinical relevance, and 
each were missing <10% of data in the MAGGIC meta-analysis. A greater number of 
variables were included in the MAGGIC HF risk score28 as multiple imputation was 
used to help account for missing data. Although different approaches were used, the 
associations between predictors and mortality in the current model are consistent 
with those found in the HF risk score. 
 
In conclusion, this large individual patient data meta-analysis has demonstrated that 
the increased risk of death among patients with anaemia is observed among those 
with HF-PEF and HF-REF and the risk is independent of other common prognostic 
variables. Although correcting anaemia for all patients does not appear to improve 
outcomes, anaemia is a marker of increased risk which should trigger greater 
vigilance in follow-up and management.  
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Table 1. Characteristics of patients with HF-REF and HF-PEF at baseline according to the 
presence or absence of anaemia.   
 Whole group HF-REF HF-PEF 
  
Anaemic  
Not 
Anaemic 
Anaemic 
Not 
Anaemic  
 
N, % (19 studies) 
 
13295 
 
4238 (32) 
 
5649 (42) 
 
1419 (11) 
 
1989 (15) 
Age, years 68 (12) 70 (12) 66 (13)** 73 (12) 69 (12)** 
Women, % 36 29 31* 53 56 
Medical history:      
   Hypertension 46 39 42** 59 61 
   Myocardial infarction 39 45 41** 29 22* 
   Atrial fibrillation 23 23 22 26 25 
   Diabetes 24 25 23* 32 23** 
   Ischaemic aetiology 56 65 55** 50 46* 
Medication      
   ACE inhibitor or ARB 82 88 87 63 67* 
   Beta-blocker 37 32 40** 34 40** 
   Diuretic 81 87 78** 82 77** 
   Spironolactone 22 23 25 17 17 
   Digoxin 40 48 42** 28 29 
Clinical status      
   NYHA class (I/II/III/IV) 17/43/29/11 10/34/41/15 17/51/24/8** 26/38/24/12 29/43/20/8** 
   Heart rate, bpm 81 (20) 81 (19) 81 (20) 80 (20) 80 (22) 
   SBP, mmHg 133 (26) 128 (26) 131 (24)** 142 (30) 144 (27) 
   DBP, mmHg 78 (14) 75 (14) 79 (14)** 77 (16) 82 (15)** 
   Haemoglobin, g/L  126 (24) 103 (17) 143 (13)** 106 (15) 141 (13)** 
   eGFR, mL/min/1.73m2 62 (25) 56 (25) 66 (24)** 56 (28) 65 (25)** 
   Oedema 29 35 23** 50 35** 
LVEF, % (median, IQR) 39 (15) 30 (24,38) 32 (24,39) 60 (54,66) 59 (54,60) 
Total deaths 2726 1325 889** 283 229** 
Data are presented as mean (standard deviation) or %.  eGFR was estimated using the 
Modification of Diet in Renal Disease (MDRD) equation. 
*p=0.001-0.05, ** p<0.001; from chi-squared or Student t-tests comparing anaemic vs not anaemic, 
within EF group.
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Table 2.  Multivariable Cox proportional hazard model for death from any cause.  
 
 
 
Adjusted hazard ratio 
(95% CI) 
 
All-cause death 
n= 11093 
Anaemia 1.38 (1.25,1.51) 
HF-REF 1.47 (1.32,1.65) 
Age, per year 1.03 (1.02,1.03) 
Male gender 1.28 (1.17,1.40) 
Atrial fibrillation 1.15 (1.05,1.23) 
Hypertension 0.92 (0.85,1.01) 
Ischaemic aetiology 1.19 (1.09,1.30) 
Diabetes 1.13 (1.03,1.24) 
eGFR, per mL/min/1.73m2 0.987 (0.985,0.989) 
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FIGURE LEGEND 
Figure 1 Hazard of all-cause mortality according to EF group and presence or 
absence of anaemia. Adjusted for age, gender, ischaemic aetiology, atrial fibrillation, 
diabetes, history of hypertension, and eGFR. 
 
Figure 2 Hazard of all-cause mortality for haemoglobin according to EF group and 
gender. Adjusted for age.
20 
 
Figure 1 
 
 
0.8 1.2 1.6 2.0 2.4 2.8
Not Anaemic
Not  Anaemic
Anaemic
Anaemic
1.00
1.59 (1.37, 1.85)
1.67 (1.39, 1.99)
Adjusted HR (95% CI)
2.49 (2.13, 2.90)
HF-PEF
HF-REF
Hazard Ratio
 
 
 
 
21 
 
Figure 2  
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